<DOC>
	<DOC>NCT01314885</DOC>
	<brief_summary>A single dose study with the inhaled anti-inflammatory agent PF-03715455 to establish if it has anti-inflammatory activity following a challenge with LPS. Inhaled LPS invokes an acute inflammatory response in the lung which can be seen in induced sputum. PH-0797804 is an internal control for the study.</brief_summary>
	<brief_title>Single Dose Lipopolysaccharide (LPS) Study In Healthy Volunteers</brief_title>
	<detailed_description>Proof of Mechanism</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Male or female (of nonchild bearing potential) subjects, aged 1850 years. Subjects whose FEV1 and FVC at screening are both greater than or equal to 80% of their predicted value for age, race, sex and height. Subjects who have normoresponsive airways. Subjects who are able to successfully complete screening sputum inductions. Subjects who have evidence, on review of prestudy laboratory data and full physical examination, or history of any clinically significant hematological, renal, endocrine, gastrointestinal, dermatological, hepatic, psychiatric, neurologic diseases. Specifically liver function tests and CRP must be within the reference range. Subjects with a medical history of asthma symptomatology (ie, wheeze and/or dyspnea at rest). Subjects who have experienced a respiratory tract infection within the previous 4 weeks or any other infection within 1 week of dosing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Healthy</keyword>
</DOC>